CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...